Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 4.70
ALIOF's Cash to Debt is ranked higher than
65% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. ALIOF: 4.70 )
ALIOF' s 10-Year Cash to Debt Range
Min: 2.7   Max: No Debt
Current: 4.7

Equity to Asset 0.72
ALIOF's Equity to Asset is ranked higher than
76% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. ALIOF: 0.72 )
ALIOF' s 10-Year Equity to Asset Range
Min: 0.5   Max: 0.72
Current: 0.72

0.5
0.72
Interest Coverage 12.30
ALIOF's Interest Coverage is ranked higher than
51% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ALIOF: 12.30 )
ALIOF' s 10-Year Interest Coverage Range
Min: 0.55   Max: 9999.99
Current: 12.3

0.55
9999.99
F-Score: 6
Z-Score: 13.03
M-Score: -1.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 30.98
ALIOF's Operating margin (%) is ranked higher than
96% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. ALIOF: 30.98 )
ALIOF' s 10-Year Operating margin (%) Range
Min: 0.68   Max: 28.36
Current: 30.98

0.68
28.36
Net-margin (%) 36.59
ALIOF's Net-margin (%) is ranked higher than
96% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. ALIOF: 36.59 )
ALIOF' s 10-Year Net-margin (%) Range
Min: -8.15   Max: 25.49
Current: 36.59

-8.15
25.49
ROE (%) 40.79
ALIOF's ROE (%) is ranked higher than
98% of the 1134 Companies
in the Global Biotechnology industry.

( Industry Median: -34.93 vs. ALIOF: 40.79 )
ALIOF' s 10-Year ROE (%) Range
Min: -8.85   Max: 53.58
Current: 40.79

-8.85
53.58
ROA (%) 25.85
ALIOF's ROA (%) is ranked higher than
98% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. ALIOF: 25.85 )
ALIOF' s 10-Year ROA (%) Range
Min: -5.18   Max: 21.05
Current: 25.85

-5.18
21.05
ROC (Joel Greenblatt) (%) 118.32
ALIOF's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. ALIOF: 118.32 )
ALIOF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 2.3   Max: 132.14
Current: 118.32

2.3
132.14
Revenue Growth (%) -0.90
ALIOF's Revenue Growth (%) is ranked higher than
77% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: -1.90 vs. ALIOF: -0.90 )
ALIOF' s 10-Year Revenue Growth (%) Range
Min: -25.8   Max: 21.5
Current: -0.9

-25.8
21.5
EBITDA Growth (%) 2.50
ALIOF's EBITDA Growth (%) is ranked higher than
80% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -4.60 vs. ALIOF: 2.50 )
ALIOF' s 10-Year EBITDA Growth (%) Range
Min: -48.4   Max: 57.6
Current: 2.5

-48.4
57.6
EPS Growth (%) 6.80
ALIOF's EPS Growth (%) is ranked higher than
83% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ALIOF: 6.80 )
ALIOF' s 10-Year EPS Growth (%) Range
Min: -35.8   Max: 47.7
Current: 6.8

-35.8
47.7
» ALIOF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

ALIOF Guru Trades in

ALIOF Guru Trades in

Q2 2012

ALIOF Guru Trades in Q2 2012

Vanguard Health Care Fund 200,000 sh (New)
» More
Q3 2012

ALIOF Guru Trades in Q3 2012

Vanguard Health Care Fund 200,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ALIOF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 18.60
ALIOF's P/E(ttm) is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 18.60 )
ALIOF' s 10-Year P/E(ttm) Range
Min: 13.52   Max: 66.51
Current: 18.6

13.52
66.51
P/B 6.80
ALIOF's P/B is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. ALIOF: 6.80 )
ALIOF' s 10-Year P/B Range
Min: 2.35   Max: 7.28
Current: 6.8

2.35
7.28
P/S 6.80
ALIOF's P/S is ranked higher than
86% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. ALIOF: 6.80 )
ALIOF' s 10-Year P/S Range
Min: 1.96   Max: 16.68
Current: 6.8

1.96
16.68
PFCF 113.20
ALIOF's PFCF is ranked higher than
92% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 113.20 )
ALIOF' s 10-Year PFCF Range
Min: 6.78   Max: 2760
Current: 113.2

6.78
2760
EV-to-EBIT 19.20
ALIOF's EV-to-EBIT is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 19.20 )
ALIOF' s 10-Year EV-to-EBIT Range
Min: -53.3   Max: 261.9
Current: 19.2

-53.3
261.9
PEG 3.10
ALIOF's PEG is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 3.10 )
ALIOF' s 10-Year PEG Range
Min: 0   Max: 4.8
Current: 3.1

0
4.8
Shiller P/E 39.70
ALIOF's Shiller P/E is ranked higher than
97% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 39.70 )
ALIOF' s 10-Year Shiller P/E Range
Min: 30.37   Max: 41.26
Current: 39.7

30.37
41.26
Current Ratio 3.95
ALIOF's Current Ratio is ranked higher than
69% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ALIOF: 3.95 )
ALIOF' s 10-Year Current Ratio Range
Min: 1.75   Max: 3.95
Current: 3.95

1.75
3.95
Quick Ratio 3.80
ALIOF's Quick Ratio is ranked higher than
70% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. ALIOF: 3.80 )
ALIOF' s 10-Year Quick Ratio Range
Min: 1.7   Max: 3.8
Current: 3.8

1.7
3.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
ALIOF's Dividend Yield is ranked higher than
52% of the 194 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. ALIOF: 0.80 )
ALIOF' s 10-Year Dividend Yield Range
Min: 0.7   Max: 1.45
Current: 0.8

0.7
1.45
Dividend Payout 0.13
ALIOF's Dividend Payout is ranked higher than
99% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 0.13 )
ALIOF' s 10-Year Dividend Payout Range
Min: 0.47   Max: 0.74
Current: 0.13

0.47
0.74
Yield on cost (5-Year) 0.80
ALIOF's Yield on cost (5-Year) is ranked higher than
51% of the 199 Companies
in the Global Biotechnology industry.

( Industry Median: 1.17 vs. ALIOF: 0.80 )
ALIOF' s 10-Year Yield on cost (5-Year) Range
Min: 0.7   Max: 1.45
Current: 0.8

0.7
1.45
Share Buyback Rate 1.70
ALIOF's Share Buyback Rate is ranked higher than
97% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -11.00 vs. ALIOF: 1.70 )
ALIOF' s 10-Year Share Buyback Rate Range
Min: 1.7   Max: -81.8
Current: 1.7

Valuation & Return

vs
industry
vs
history
Price/Net Cash 39.60
ALIOF's Price/Net Cash is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 64.50 vs. ALIOF: 39.60 )
ALIOF' s 10-Year Price/Net Cash Range
Min: 11.79   Max: 75.62
Current: 39.6

11.79
75.62
Price/Net Current Asset Value 36.30
ALIOF's Price/Net Current Asset Value is ranked higher than
73% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 34.97 vs. ALIOF: 36.30 )
ALIOF' s 10-Year Price/Net Current Asset Value Range
Min: 10.97   Max: 258.81
Current: 36.3

10.97
258.81
Price/Tangible Book 9.60
ALIOF's Price/Tangible Book is ranked higher than
71% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9.12 vs. ALIOF: 9.60 )
ALIOF' s 10-Year Price/Tangible Book Range
Min: 2.98   Max: 10.28
Current: 9.6

2.98
10.28
Price/DCF (Projected) 2.60
ALIOF's Price/DCF (Projected) is ranked higher than
96% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 2.60 )
ALIOF' s 10-Year Price/DCF (Projected) Range
Min: 1.57   Max: 2.72
Current: 2.6

1.57
2.72
Price/Median PS Value 1.90
ALIOF's Price/Median PS Value is ranked higher than
77% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. ALIOF: 1.90 )
ALIOF' s 10-Year Price/Median PS Value Range
Min: 0.6   Max: 4.71
Current: 1.9

0.6
4.71
Price/Graham Number 2.70
ALIOF's Price/Graham Number is ranked higher than
95% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ALIOF: 2.70 )
ALIOF' s 10-Year Price/Graham Number Range
Min: 1.4   Max: 2.97
Current: 2.7

1.4
2.97
Earnings Yield (Greenblatt) 5.20
ALIOF's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. ALIOF: 5.20 )
ALIOF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 13.3
Current: 5.2

0.4
13.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:ATLNE.Switzerland, ATLN.Switzerland, ACT.Germany, 0QMN.UK
Actelion Ltd was founded on December 17, 1997 and is headquartered in Allschwil, Switzerland. The Company is a biopharmaceutical company, that engages in the discovery, development, and commercialization of low molecular weight drugs for unmet medical needs. It is engaged in the field of pulmonary arterial hypertension (PAH). Its portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Its products portfolio includes Opsumit (Macitentan), Tracleer (Bosentan), Valchlor (Mechlorethamine), Zavesca (Miglustat), Veletri (Epoprostenol For Injection), and Ventavis (Iloprost).
» More Articles for ALIOF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Actelion Misses Q3 Earnings Expectation, Ups 2014 Guidance Oct 22 2014
Ligand Up on Multi-Program Captisol Deal with Avion Pharma Aug 18 2014
Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data Aug 18 2014
Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up Aug 18 2014
TrovaGene (TROV) Worth Watching: Stock Rises 8.8% Aug 18 2014
NewLink Genetics Corp. (NLNK) Jumps: Stock Adds 8.6% in Session Aug 18 2014
Epizyme (EPZM) Crumbles: Stock Falls by 5.9% Aug 18 2014
Achillion Pharmaceuticals (ACHN) in Focus: Stock Up 9.6% Aug 18 2014
Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails Aug 14 2014
Genomic Health Raised to Buy on Better-than-Expected Q2 Aug 14 2014
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up Aug 14 2014
InterMune (ITMN) Jumps: Stock Adds 14.4% in Session Aug 14 2014
Insmed Incorporated (INSM) in Focus: Stock Up 10.9% Aug 14 2014
Dendreon Down on Default Risk, Reports Narrower Q2 Loss Aug 13 2014
BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues Aug 13 2014
Myriad Genetics' Q4 Earnings Beat Estimates, Revenues Up Y/Y Aug 13 2014
Intercept Pharmaceuticals (ICPT) Worth Watching: Stock Gains 16.6% Aug 13 2014
Regeneron's Eye Drug Eylea Cleared in the EU for DME Aug 12 2014
Sarepta Therapeutics Reports Wider Y/Y Loss, Revenues Miss Aug 12 2014
MannKind Posts Wider Q2 Loss, Up on Sanofi Deal for Afrezza Aug 12 2014
OvaScience (OVAS) Shows Strength: Stock Up 7% Aug 12 2014
Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK